Table 6.
Second-line endocrine therapy in patients with HR-positive, HER2-negative breast cancer resistant to treatment with nonsteroidal aromatase inhibitors.
| Therapy | n | Median PFS/Median TTP, Months | Source/Study |
|---|---|---|---|
| Exemestane | 249 | 3.4 | Johnston et al./SoFEA [35] |
| Fulvestrant | 231 | 4.8 | Johnston et al./SoFEA [35] |
| Fulvestrant + anastrozole | 243 | 4.4 | Johnston et al./SoFEA [35] |
| Exemestane | 362 | 4.1 | Baselga et al./BOLERO-2 [36] |
| Everolimus + exemestane | 485 | 10.6 | Baselga et al./BOLERO-2 [36] |
| Exemestane | 351 | 3.7 | Chia et al./EFECT [37] |
| Fulvestrant | 342 | 3.7 | Chia et al./EFECT [37] |
| Fulvestrant, 250 mg | 374 | 5.5 | Di Leo et al./CONFIRM [38] |
| Fulvestrant, 500 mg | 362 | 6.5 | Di Leo et al./CONFIRM [38] |
PFS—progression-free survival; TTP—time to progression.